

Ending Cancer As We Know It – For All

Douglas R. Lowy, M.D.

Principal Deputy Director, National Cancer Institute

October 12, 2022

*11th Virtual Meeting of the Frederick National Laboratory
Advisory Committee (FNLAC)*

@NCIDirector
@TheNCI

Welcome! New FNLAC Members

Mary J. C. Hendrix, Ph.D. (*Chair*)

Shepherd University

Rodney J.Y. Ho, Ph.D.

University of Washington

Anant Madabhushi, Ph.D.

Georgia Institute of Technology and Emory University

Carol J. Bult, Ph.D.

The Jackson Laboratory

Angela M. Gronenborn, Ph.D.

University of Pittsburgh School of Medicine

Today's Talk

- NCI News and Updates
- Research Advances
- Cancer Moonshot
- Budget Update & Annual Plan and Budget Proposal for Fiscal Year 2024

New NCI Director: Dr. Monica Bertagnolli




“Working together, I believe that *there is nothing we can’t do*, in partnership with our many colleagues in the broader cancer community.”

Federally Funded Research and Development Center (FFRDC) Recompetition – Update

- Request For Proposals was released on June 23, 2022
- Current Proposal Due date: February 20, 2023
- Planning a Pre-Proposal Conference scheduled for late Fall 2022.
- Developing plans for in-person tour of the NCI Frederick space on Fort Detrick
- Award date is planned for some time in 2024 (tentative).



The Fourth RAS Initiative Symposium



RAS
INITIATIVE

Symposium

October 17–19, 2022

Hosted by the Frederick National Laboratory for Cancer Research
and the National Cancer Institute.

Goal of the RAS Initiative:

Develop ways to **understand and target cancers driven by mutant RAS** *in an open model of collaboration among government, academic, and industry researchers.*

For more:

ncifrederick.cancer.gov/events/conferences/fourth-ras-initiative-symposium

FNLCR Awareness Campaign Updates

**New video marking
10 years of FNLCR
as a national lab**

***Cancer Currents*
blog post next
month**

**Survey of
Extramural
Researchers**

*Findings will inform ongoing
strategies*

White House Forum on Childhood Cancer

In recognition of National Childhood Cancer Awareness Month

September 23, 2022



Photo: White House Office of Science and Technology Policy

Community-driven event hosted by the White House Office of Science and Technology Policy

Organized in collaboration with:

- Alliance for Childhood Cancer
- Coalition Against Childhood Cancer (CAC2)

NCI Panelists:

- **Dr. Greg Reaman**, incoming Scientific Director, NCI Childhood Cancer Data Initiative (CCDI)
- **Dr. Stephen Chanock**, Director, NCI Division of Cancer Epidemiology & Genetics (DCEG)


Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer

- On August 11, the FDA gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with *HER2*-mutant non-small cell lung cancer (NSCLC).
 - Around 3% of people with NSCLC have this kind of *HER2* mutation.
- **Marks the first time patients with *HER2*-mutant NSCLC have an FDA-approved targeted therapy option.**



Vulnerability in Brain Tumors May Open Door to New Treatments


- Two recent NCI-supported studies uncovered a vulnerability in different forms of gliomas (dependence on de novo pyrimidine nucleotide synthesis).
- **A drug (BAY 2402234) may be able to exploit this vulnerability for the benefit of patients with gliomas.**
- Next step: clinical trial (will be sponsored by NCI's Glioblastoma Therapeutics Network).
- The work outlines **a tumor-selective, biomarker-guided therapeutic strategy that is *poised for clinical translation.***



To explore potential treatments for gliomas, researchers developed organoids (pictured) using tumor samples donated by people with these lethal brain cancers.

Teclistamab Shows Promise for People with Heavily Pretreated Multiple Myeloma

- New results from a clinical trial that tested an **experimental immunotherapy drug teclistamab** (Tecvayli) in people with multiple myeloma that did not respond to 3+ different cancer treatments:
 - **Nearly two-thirds of participants had at least a partial response**
 - **Almost 40% had complete remission**
- ***People with advanced multiple myeloma (second most common blood cancer) may soon have another treatment option.***
- Trial: MajesTEC-1 (funded by Janssen)



Technology Development & Health Disparities

Technology can
decrease disparities,
increase disparities, or
be neutral

To increase the likelihood of a technological development decreasing disparities, **think about disparities *from the beginning* of the process**

Don't wait until the end to consider the possible impact on disparities

Even more direct: develop technology whose **goal includes reducing disparities**

15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

September 16-19, 2022

Some take-home messages from my keynote address:



We have made some progress – but still have a long way to go address this multifaceted problem.



We must be inclusive in our research and the cancer research workforce.



We all have a role to play – whether focused on the U.S. or low- and middle-income countries. **Our roles can span a wide range of research:** from technology development aimed at reducing disparities – to research on affected populations.

Ending
Cancer
As We
Know It
For All



President Biden Details Cancer Moonshot Progress

On the 60th Anniversary of President Kennedy's Moonshot Address

September 12, 2022



“Beating cancer is something we can do together. And that’s why I’m here today.”

“I believe we can usher in the same unwillingness to postpone, the same national purpose that will serve to organize and measure the best of our energies and skills to end cancer as we know it – and even cure cancers once and for all.”

President Biden, September 12, 2022

John F. Kennedy Presidential Library and Museum

Cancer Moonshot Next Phase

Jumpstarting Three Programs



The screenshot shows the NIH National Cancer Institute website. The header includes the NIH logo and the text "NATIONAL CANCER INSTITUTE". Below the header is a navigation bar with links for "ABOUT CANCER", "CANCER TYPES", "RESEARCH", "GRANTS & TRAINING", "NEWS & EVENTS", and "ABOUT NCI". A search bar is also present. The main content area is titled "About the Cancer MoonshotSM" and includes a sidebar with a "CANCER MOONSHOTSM" section. The sidebar lists "About the Cancer Moonshot", "Progress", "Research Initiatives", "Seminar Series", "Funding Opportunities", and "Blue Ribbon Panel". The main content area has a section titled "ON THIS PAGE" with two bullet points: "New Cancer Moonshot Research Goals" and "New and Upcoming Cancer Moonshot Programs". Below this is a paragraph of text starting with "The Cancer Moonshot, initially funded through the 21st Century Cures Act passed in..."



CANCER MOONSHOT
SCHOLARS



TELEHEALTH



MULTI-CANCER DETECTION

Learn more: cancer.gov/moonshot



Increasing enrollment of underrepresented groups to NCI clinical trials: New phase of Cancer Moonshot



Goal: Mimic at-risk population for the specific cancer studied



Need **greater investment** (e.g., community engagement)



More diversity among **health care providers**

Increasing enrollment of underrepresented groups to NCI clinical trials: *A long-term commitment*

NCI Clinical Trials

NCORP: NCI Community Oncology Research Program

NCTN: NCI's National Clinical Trials Network

| 1999-2001 | 2017-2019 |
|--------------|--------------|
| 14% minority | 25% minority |

- Most of the increase has been in Black/African American and Hispanic populations

NCI Summit on Increasing Diversity, Equity and Inclusion in Early Phase Clinical Trials (Nov. 16, 2022)

Aim: Identify and discuss the implementation of best practices for increasing inclusion and equity in NCI cancer clinical trials.

Hosted by NCI Equity & Inclusion Program

November 16, 2022

Registration information forthcoming at cancer.gov and Twitter (@theNCI)

Session topics (tentative):

- ✓ Regulatory expectations and policies for increasing diversity in clinical trials
- ✓ DEI success stories
- ✓ Hearing from community health workers and patient advocates
- ✓ Partnerships to promote equity and inclusion in NCI trials

Annual Plan & Budget Proposal for Fiscal Year 2024

Available at:

cancer.gov/research/annual-plan



Annual Plan & Budget Proposal for Fiscal Year 2024

Highlighted Scientific Opportunities:



ASYMPTOMATIC MULTI-CANCER DETECTION



CELL THERAPY TO TREAT CANCER



PERSISTENT POVERTY AND CANCER



UNDRUGGABLE CANCER TARGETS




cancer.gov/research/annual-plan

Professional Judgment Budget Proposal for Fiscal Year 2024

| PROFESSIONAL JUDGMENT BUDGET PROPOSAL FOR FISCAL YEAR 2024 (DOLLARS IN MILLIONS) | | |
|--|-----------------|---|
| Prior (FY 2023) Professional Judgment Budget Proposal | \$7,550* | |
| Proposed Budget Increase for FY 2024 to Seize Opportunities for Progress | \$1,166 | \$354 Cancer Biology Research \$247 Cancer Prevention Research \$192 Cancer Detection & Diagnosis Research \$227 Cancer Treatment Research \$86 Public Health & Cancer Control Research \$60 Training & Infrastructure |
| Funding to Revolutionize Cancer Clinical Research [†] | \$1,272 | |
| FY 2024 TOTAL | \$9,988 | |

*This proposal includes \$50 million for the Childhood Cancer Data Initiative, a 10-year initiative that began in FY 2020.
[†]This proposed funding will be used to achieve the goals of reducing cancer death rates by 50% over the next 25 years and ending cancer as we know it for all.

President's NCI Budget and Enacted Appropriations



Source: NCI Budget Fact Book

- Strong bipartisan support for cancer research across Congress
- Congress has declined to cut funding to cancer research – even in challenging budget cycles

Thank you!

www.cancer.gov

www.cancer.gov/espanol

1-800-4-CANCER

NCInfo@nih.gov

[@NCIDirector](#)

[@TheNCI](#)



**NATIONAL
CANCER
INSTITUTE**

Thank You!

Frederick National Laboratory Advisory Committee (FNLAC)

2022 Retiring Members

Catherine M. Bollard, M.D.

Children's National Hospital
The George Washington University

Lincoln D. Stein, M.D., Ph.D.

Ontario Institute for Cancer Research
University of Toronto